A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1794-1799

  Rini, B ^a   Redman, B ^b   Garcia, J A ^a   Burris, H A ^c   Li, S ^d   Fandi, A ^d   Beck, R ^d   Jungnelius, U ^d   Infante, J R ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

Lenalidomide; Maximum tolerated dose; Metastatic renal cell carcinoma; Phase I II; Sunitinib

Indexed keywords

LENALIDOMIDE; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; B LYMPHOCYTE; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEHYDRATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERKALEMIA; HYPERURICEMIA; IMMUNOMODULATION; KIDNEY METASTASIS; LEUKOPENIA; LYMPHOCYTE SUBPOPULATION; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR VOLUME; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PYRROLES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84906854146     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu212     Document Type: Article

References (22)

1. Turner KJ, Moore JW, Jones A et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62: 2957-2961.
2. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v2.2014; http://www.nccn.org/professionals/physician_ gls/pdf/kidney.pdf (March 2014, date last accessed).
5. Cho DC, Atkins MB. Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am 2011; 25: 917-935.
6. Choueiri TK, Dreicer R, Rini BI et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2609-2616.
7. Amato RJ, Hernandez-McClain J, Saxena S, Khan M. Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 2008; 31: 244-249.
8. Blansfield JA, Caragacianu D, Alexander HR III et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008; 14: 270-280.
9. Schneiderman MA. Mouse to man: statistical problems in bringing a drug to clinical trial. In Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability 1967; 4: 855-866.
10. Gandhi AK, Kang J, Capone L et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155-167.
11. US Department of Health and Human Services. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (3 March 2014, date last accessed).
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
13. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
14. Patel PH, Kondagunta GV, Schwartz L et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 2008; 26: 273-276.
15. Agliano A, Martin-Padura I, Marighetti P et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res 2011; 17: 6163-6173.
16. Vroling L, van der Veldt AA, de Haas RR et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009; 12: 69-79.
17. Tageja N. Lenalidomide-current understanding of mechanistic properties. Anticancer Agents Med Chem 2011; 11: 315-326.
18. Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1432-1439.
19. Molina AM, Feldman DR, Voss MH et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012; 118: 1868-1876.
20. Michaelson MD. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street? Cancer 2012; 118: 1744-1746.
21. Rini BI, Bellmunt J, Clancy J et al. Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. Ann Oncol 2012; 23(Suppl 9): abstr LBA21_PR.
22. Ravaud A, Barrios C, Anak ö et al. Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2a (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (MRCC): RECORD-2. Ann Oncol 2012; 23(Suppl 9): abstr 783O.